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coronary angiography is critical to rule out the diagnosis of
typical myocardial infarction and to allow for the arrival at
the correct diagnosis of Takotsubo cardiomyopathy. On the
other hand, emergency coronary angiography is more
invasive for the patient undergoing emergency surgery.
Especially in the patient who has a ruptured aortic aneu-
rysm, oozing from the retroperitoneal small vessels injured
by hematoma or surgical procedure is of concern because
of the use of anticoagulants for catheterization. In our
patient, despite a large blood transfusion including the
platelet concentrates, platelet count on ICU admission
was 6.0 3 104/mL. Therefore, we initially obtained trans-
thoracic echocardiography by a cardiologist. According
to the typical findings of Takotsubo cardiomyopathy re-
vealed by echocardiography, normal creatine kinase MB
fraction, and stable hemodynamic status, we selected care-
ful observation.
We routinely perform preoperative coronary angiogra-
phy to assess the risk of perioperative myocardial infarc-
tion. Although preoperative intact coronary angiography
is also meaningful to avoid needless or harmful coronary
angiography in the perioperative period, as in the case
with our patient, preoperative screening for heart disease
is often limited to an electrocardiogram in emergency cases.
However, in a certain situation, Takotsubo cardiomyopathy
could be diagnosed by integration of clinical noninvasive
modalities.
We described the first case of Takotsubo cardiomyopathy
after ruptured abdominal aortic aneurysm repair. We consid-
ered that diagnosis of this syndrome could be and should be
made without invasive coronary angiography in certain sit-
uations to avoid further complications.
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Brief CommunicationsDo statins delay the progression of aortic stenosis?
Hisato Takagi, MD, PhD, Norikazu Kawai, MD, and Takuya Umemoto, MD, PhD, Shizuoka, JapanCalcific aortic stenosis (AS) is the most common form of
valvular heart disease in the Western world, and the only es-
tablished therapy for patients with severe symptomatic AS is
surgical valve replacement. There are currently no effective
disease-modifying treatments, and the possibility of halting
the disease process would represent a therapeutic advance.1
Although some observational studies2-4 demonstrated that
statins (hydroxymethylglutaryl-coenzyme A reductase in-
hibitors) delayed the progression of AS, a randomized con-
trolled trial1 concluded that intensive lipid-lowering therapy
with atorvastatin did not halt its progression. Furthermore,
no meta-analysis of studies of statins for AS has been con-
ducted to date. Therefore, the appropriate role of statins
From the Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka,
Japan.
Received for publication March 4, 2008; accepted for publication March 14, 2008.
Address for reprints: Hisato Takagi, MD, PhD, Department of Cardiovascular Surgery,
Shizuoka Medical Center, 762–1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka
411–8611, Japan (E-mail: kfgth973@ybb.ne.jp).
J Thorac Cardiovasc Surg 2009;137:e6-9
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.03.018e6 The Journal of Thoracic and Cardiovascular Surfor AS remains unclear. We performed a meta-analysis of
comparative studies of statins for the prevention of the pro-
gression of AS.
CLINICAL SUMMARY
All comparative studies of statins versus control (no
statins or placebo) for AS were identified using a 2-level
search strategy. First, a public domain database (MEDLINE)
was searched using a Web-based search engine (PubMed).
Second, relevant studies were identified through a manual
search of secondary sources, including references of initially
identified articles and a search of reviews and commentaries.
The MEDLINE database was searched from January of 1966
to January of 2008. MeSH keywords included ‘‘hydroxyme-
thylglutaryl-CoA reductase inhibitors’’ and ‘‘aortic valve
stenosis.’’ Studies considered for inclusion met the follow-
ing criteria: The design was a comparative study, and the
study population comprised patients with AS. Patients
were assigned to statins versus control (no statins or pla-
cebo), and the main outcomes included annualized changes
of echocardiographic characteristics. Data regarding detailedgery c January 2009
Brief CommunicationsTABLE 1. Baseline patient characteristics and outcomes
Mohler and colleagues5 Moura and colleagues2 Cowell and colleagues1
Design Prospective cohort Prospective cohort Randomized controlled
Statin type NR Rosuvastatin Atorvastatin
Follow-up 1 y 18 mo (73  24 wk) 2 y (median 25 [7–36] mo)
Statin NR NR NR
No statin
P valuey
Inclusion criteria 0.7  AVA  2.0 cm2 1.0  AVA  1.5 cm2 PAJV  2.5 m/sec
Patients (N)
Statin 39 61 65
No statin 22 60 69
Age (y)
Statin 69.5  9.7 73.4  8.5 68  11
No statin 63.9  10.1 73.9  9.4 68  10
P valuey NR .749 NS
Baseline TC (mg/dL)
Statin 174  36 243.0  40.5 220  38
No statin 205  28 192.0  45.8 217  34
P valuey NR <.001 NS
Baseline PAJV (m/s)
Statin NR 3.65  0.64 3.39  0.62
No statin 3.62  0.61 3.45  0.67
P valuey .788 NS
Baseline AVA (cm2)
Statin 1.13  0.27 1.23  0.42 1.03  0.4
No statin 1.22  0.25 1.20  0.35 1.02  0.41
P valuey .18 .636 NS
Annualized increase in PAJV
Statin NR 0.04  0.38 (m/s/y) 0.199  0.210 (m/s/y)
No statin 0.24  0.30 (m/s/y) 0.203  0.208 (m/s/y)
P valuey .007 .95
Annualized decrease in AVA
Statin 5.81  14.5 (%/y) 0.05  0.12 (cm2/y) 0.079  0.107 (cm2/y)
No statin 8.54  29.1 (%/y) 0.10  0.09 (cm2/y) 0.083  0.107 (cm2/y)
P valuey .10 .041 .68
AS, Aortic stenosis; AVA, aortic valve area; HC, hypercholesterolemia; IQR, interquartile range; MG, mean gradient; NR, not reported; NS, not significant; PAJV, peak aortic jet
velocity; TC, total cholesterol. Values are expressed as mean SD. *Value in 121 patients including 26 with aortic valve sclerosis (1.5<PAJV<2 m/s). yValue reported in each
individual study.inclusion criteria, statin type, duration of follow-up, and
echocardiographic characteristics were abstracted (as avail-
able) from each individual study. We conducted a meta-anal-
ysis of summary statistics from the individual studies
because detailed, patient-level data were not available for
all studies. For each study, data regarding annualized ‘‘in-
crease’’ in peak aortic jet velocity (PAJV) and annualized
‘‘decrease’’ in aortic valve area (AVA) in both the statin
and control groups were used to generate standardized
mean differences (SMDs) (<0 favors statins;>0 favors con-
trol) and 95% confidence intervals (CIs). Study-specific es-The Journal of Thoracic andtimates were combined using both fixed- and random-effects
models. Between-study heterogeneity was analyzed by
means of standard chi-square tests. Where statistically sig-
nificant heterogeneity was identified, the random-effects
estimate was used preferentially as the summary measure.
Publication bias was assessed mathematically using an
adjusted rank-correlation test.
RESULTS
Our search identified 7 comparative studies1-7 of statins
versus control for AS. These included 1randomizedCardiovascular Surgery c Volume 137, Number 1 e7
Brief CommunicationsAntonini-Canterin and colleagues6 Rosenhek and colleagues3 Bellamy and colleagues4 Novar and colleagues7
Retrospective cohort Retrospective cohort Prospective cohort Retrospective cohort
Simvastatin Simvastatin Simvastatin Simvastatin
Atorvastatin Atorvastatin Lovastatin, and so forth Lovastatin
Pravastatin Pravastatin, and so forth Pravastatin
Fluvastatin Atorvastatin
Cerivastatin Fluvastatin
6 mo 6 (24  18) mo 6 mo 12 (21  7 [12–40]) mo
54  34 mo NR 3.7  2.1 y NR
50  33 mo 3.7  2.3 y
.35 .94
Mild AS Moderate AS PAJV>2.5 m/sec MG  10 mm Hg 1.0  AVA  1.8 cm2
2  PAJV<3 m/sec 3  PAJV<4 m/sec AVA  2.0 m2
63 32 50 38 57
63 32 161 118 117
67  9* 72  8 73  11 71  9
67  9* 69  11 78  12 67  13
NS <.05 .03 .01
HC: 92%* 232  48 246  58 Median 210 (IQR, 193–241)
HC: 14%* 219  41 214  45 Median 208 (IQR, 186–227)
<.001 NS <.01 .41
2.45  0.66* 4.08  0.86 2.8  0.5 NR
2.44  0.65* 3.92  0.86 3.0  0.8
.95 NS NR
NR 0.82  0.23 1.32  0.29 1.2 (IQR, 1.0–1.4)
0.84  0.23 1.20  0.35 1.2 (IQR, 1.0–1.4)
NS .04 .71
0.11  0.25 (m/s/y) 0.23  0.27 (m/s/y) 0.10  0.41 (m/s/y) 5  8 (%/y) NR
0.10  0.17 (m/s/y) 0.24  0.23 (m/s/y) 0.39  0.42 (m/s/y) 9  12 (%/y)
.79 .92 .0001 .03
NR NR 3  10 (%/y) 0.06  0.16 (cm2/y)
7  13 (%/y) 0.11  0.18 (cm2/y)
.04 NR
TABLE 1. Continuedcontrolled trial,1 3 prospective cohort studies,2,4,5 and 3 ret-
rospective cohort studies.3,6,7 The baseline patient charac-
teristics and outcomes are summarized in Table 1. We did
not pool annualized changes in peak and mean aortic valve
pressure gradients because only 2 studies reported them. For
annualized ‘‘increase’’ in PAJV, 2 studies by Moura and as-
sociates2 and Rosenhek and colleagues3 demonstrated a sta-
tistically significant benefit of statins over control. Pooled
analysis (representing 812 patients) demonstrated a statisti-
cally significant reduction in annualized ‘‘increase’’ of
PAJV with statins relative to control in the random-effectse8 The Journal of Thoracic and Cardiovascular Surgmodel (SMD, –0.28; 95% CI, –0.55 to –0.01; P¼ .04) (Fig-
ure 1, A). There was significant between-study heterogene-
ity of results (P < .01) but no evidence of significant
publication bias (P ¼ .09). For annualized ‘‘decrease’’ in
AVA, the study by Moura and coworkers2 demonstrated
a statistically significant benefit of statins over control, but
the study by Mohler and associates5 demonstrated a statisti-
cally significant benefit of control over statins. Pooled anal-
ysis (representing 646 patients) demonstrated a statistically
nonsignificant reduction in annualized ‘‘decrease’’ of AVA
with statins relative to control in the random-effects modelery c January 2009
Brief CommunicationsFIGURE 1. Outcomes and meta-analyses. A, Annualized ‘‘increase’’ in PAJV. B, Annualized ‘‘decrease’’ in AVA. SD, Standard deviation; SMD, standard-
ized mean difference; CI, confidence interval.(SMD, –0.12; 95% CI, –0.44 to 0.20; P ¼ .46) (Figure 1,
B). There was significant between-study heterogeneity of
results (P< .01) but no evidence of significant publication
bias (P ¼ 1.00). For a sensitivity analysis, the study by
Mohler and colleagues5 was excluded, which only demon-
strated a statistically significant benefit of control over
statins; combining the remaining studies generated an
attenuated and statistically significant result favoring statins
(random-effects SMD, –0.26; 95% CI,–0.45 to –0.07;
P< .01).
DISCUSSION
On the basis of the present meta-analysis, statins are likely
to delay the progression of AS: reducing not ‘‘decrease’’ in
AVA but ‘‘increase’’ in PAJV. These results should be inter-
preted with caution, because the design was nonrandomized
observational in all studies but one in our meta-analysis, and
there was qualitative heterogeneity in patient selection. The
completion of ongoing randomized controlled trials8,9 is
expected to confirm the present results.The Journal of Thoracic andReferences
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